Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coe, C.
Right arrow Articles by Barnes, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Coe, C.
Right arrow Articles by Barnes, P.

Chest, Vol 90, 485-488, Copyright © 1986 by American College of Chest Physicians

ARTICLES

Reduction of nocturnal asthma by an inhaled anticholinergic drug

CI Coe and PJ Barnes

Although the mechanisms of nocturnal asthma are still uncertain, increased vagal cholinergic tone may be contributory factor. To examine this hypothesis, we have studied the effect of an anticholinergic drug, oxitropium bromide, on the early morning fall in peak expiratory flow (PEF) in patients with nocturnal asthma. Eighteen patients (aged 18 to 76 years; seven men) with documented nocturnal asthma were studied in a double-blind randomized cross-over study in which they received either oxitropium bromide (200 micrograms or 400 micrograms) or placebo in a single dose at night for two-week periods. With placebo the mean (+/- SE) fall in PEF (expressed as percentage of evening PEF) was 17.3 +/- 2.0 percent, which was significantly reduced to 10.3 +/- 3.3 percent after oxitropium (400 micrograms) (p less than 0.05; ANOVA). Closer analysis revealed that nine of the 18 patients had responded in a dose- dependent manner, with the mean percentage decreases with placebo, 200 micrograms, and 400 micrograms of oxitropium being 19.1 +/- 3.2, 11.5 +/- 4.4, and 5.0 +/- 4.5 percent, respectively (p less than 0.01 between each treatment). The remaining patients were unaffected by therapy. There were no differences between "responders" and "non- responders" in terms of age, atopic status, duration of asthma, severity of asthma, or bronchodilator response to albuterol (salbutamol). There were no differences in nocturnal symptoms between periods of treatment, and no side effects were recorded. We conclude that anticholinergic drugs may protect against nocturnal asthma in some patients, indicating the involvement of vagal cholinergic mechanisms.


This article has been cited by other articles:


Home page
 ThoraxHome page
P M A Calverley, A Lee, L Towse, J van Noord, T J Witek, and S Kelsen
Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease
Thorax, October 1, 2003; 58(10): 855 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. G. IRVIN, J. PAK, and R. J. MARTIN
Airway-Parenchyma Uncoupling in Nocturnal Asthma
Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 50 - 56.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. J. MARTIN and S. BANKS-SCHLEGEL
Chronobiology of Asthma
Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 1002 - 1007.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American College of Chest Physicians.